Meeting
2019 ASCO Annual Meeting
T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial).
Authors
Alexandre Reuben
Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Alexandre Reuben , Jianjun Zhang , Heather Y. Lin , Latasha Little , Curtis Gumbs , Hai T. Tran , Linghua Wang , Cara L. Haymaker , Reza J. Mehran , David C. Rice , Garrett L. Walsh , J. Jack Lee , Ignacio Ivan Wistuba , Stephen Swisher , Ara A. Vaporciyan , Andrew Futreal , Boris Sepesi , John Heymach , Don Lynn Gibbons , Tina Cascone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03158129
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8532)
DOI
10.1200/JCO.2019.37.15_suppl.8532
Abstract #
8532
Poster Bd #
288
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
First Author: Robert L. Ferris
Poster
2023 ASCO Annual Meeting
High-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colon cancer: The ALFEO pilot study.
First Author: Andrea Sartore-Bianchi
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
First Author: Ralph Zinner
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial.
First Author: Filiz Oezkan